img

Global Infectious Vaccines Industry Research Report, Growth Trends and Competitive Analysis 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Infectious Vaccines Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

A vaccine is a medical product primarily designed to stimulate antibodies against an infectious disease which help to improve the immunity of the target body.
The global Infectious Vaccines market size was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034.
Rising consumer awareness regarding health coupled with rising disposable income is expected to propel demand for infectious vaccines over the next seven years. Furthermore, increasing government activities to control epidemic diseases such as polio, camp fever, and swine flu is projected to have impact market growth significantly over the next seven years.
In terms of sales (consumption) side, this report focuses on the sales of Infectious Vaccines by regions (Countries), company, by type and by type. from 2018 to 2023 and forecast to 2034.
The global Infectious Vaccines market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of sales analysis, the authors of the report have provided reliable estimations and calculations for global revenue and sales by type segment of the global Infectious Vaccines market. These figures have been provided in terms of both revenue and sales for the period 2018-2034. Additionally, the report provides accurate figures for sales by region in terms of revenue as well as volume for the same period.



By Company


CSL Limited (Australia)
Bavarian Nordic (Denmark)
GlaxoSmithKline plc. (U.K.)
Emergent Bio Solutions Inc. (U.S.)
MedImmune LLC (U.S.)
Johnson and Johnson (U.S.)
Novartis AG (Switzerland)
Merck and Company (U.S.)
Sanofi Pasteur (France)
Pfizer Inc. (U.S.)
By Type
Preventive Vaccine
Therapeutic Vaccine
By Application
Adults
Pediatrics
Sales by Region
North America
U.S.
Canada
China
APAC (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Sales (consumption), revenue of Infectious Vaccines in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3Detailed analysis of Infectious Vaccines manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 7Europe by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 8China by company, by type and by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by company, by type, by application and by region, sales, and revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 11Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Infectious Vaccines sales, revenue, price, gross margin, and recent development, etc.
Chapter 12Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14The main points and conclusions of the report.

Table of Content

1 Report Overview
1.1 Infectious Vaccines Definition
1.2 Market by Type
1.2.1 Global Infectious Vaccines Market Size Growth Rate by Type, 2018 VS 2024 VS 2034
1.2.2 Preventive Vaccine
1.2.3 Therapeutic Vaccine
1.3 Market Segment by Application
1.3.1 Global Infectious Vaccines Market Size Growth Rate by Application, 2018 VS 2024 VS 2034
1.3.2 Adults
1.3.3 Pediatrics
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Infectious Vaccines Sales
2.1 Global Infectious Vaccines Revenue Estimates and Forecasts 2018-2034
2.2 Global Infectious Vaccines Revenue by Region: 2018 VS 2024 VS 2034
2.3 Global Infectious Vaccines Revenue by Region
2.3.1 Global Infectious Vaccines Revenue by Region (2018-2023)
2.3.2 Global Infectious Vaccines Revenue by Region (2024-2034)
2.4 Global Infectious Vaccines Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Infectious Vaccines Sales Quantity by Region: 2018 VS 2024 VS 2034
2.6 Global Infectious Vaccines Sales Quantity by Region
2.6.1 Global Infectious Vaccines Sales Quantity by Region (2018-2023)
2.6.2 Global Infectious Vaccines Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Infectious Vaccines Sales Quantity by Manufacturers
3.1.1 Global Infectious Vaccines Sales Quantity by Manufacturers (2018-2023)
3.1.2 Global Infectious Vaccines Sales Quantity Share by Manufacturers (2018-2023)
3.1.3 Global Top 10 and Top 5 Companies by Infectious Vaccines Sales in 2024
3.2 Global Infectious Vaccines Revenue by Manufacturers
3.2.1 Global Infectious Vaccines Revenue by Manufacturers (2018-2023)
3.2.2 Global Infectious Vaccines Revenue Share by Manufacturers (2018-2023)
3.2.3 Global Top 10 and Top 5 Companies by Infectious Vaccines Revenue in 2024
3.3 Global Infectious Vaccines Sales Price by Manufacturers
3.4 Global Key Players of Infectious Vaccines, Industry Ranking, 2021 VS 2024
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Infectious Vaccines Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Infectious Vaccines, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Infectious Vaccines, Product Offered and Application
3.8 Global Key Manufacturers of Infectious Vaccines, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Infectious Vaccines Sales Quantity by Type
4.1.1 Global Infectious Vaccines Historical Sales Quantity by Type (2018-2023)
4.1.2 Global Infectious Vaccines Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Infectious Vaccines Sales Quantity Market Share by Type (2018-2034)
4.2 Global Infectious Vaccines Revenue by Type
4.2.1 Global Infectious Vaccines Historical Revenue by Type (2018-2023)
4.2.2 Global Infectious Vaccines Forecasted Revenue by Type (2024-2034)
4.2.3 Global Infectious Vaccines Revenue Market Share by Type (2018-2034)
4.3 Global Infectious Vaccines Price by Type
4.3.1 Global Infectious Vaccines Price by Type (2018-2023)
4.3.2 Global Infectious Vaccines Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Infectious Vaccines Sales Quantity by Application
5.1.1 Global Infectious Vaccines Historical Sales Quantity by Application (2018-2023)
5.1.2 Global Infectious Vaccines Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Infectious Vaccines Sales Quantity Market Share by Application (2018-2034)
5.2 Global Infectious Vaccines Revenue by Application
5.2.1 Global Infectious Vaccines Historical Revenue by Application (2018-2023)
5.2.2 Global Infectious Vaccines Forecasted Revenue by Application (2024-2034)
5.2.3 Global Infectious Vaccines Revenue Market Share by Application (2018-2034)
5.3 Global Infectious Vaccines Price by Application
5.3.1 Global Infectious Vaccines Price by Application (2018-2023)
5.3.2 Global Infectious Vaccines Price Forecast by Application (2024-2034)
6 North America
6.1 North America Infectious Vaccines Sales by Company
6.1.1 North America Infectious Vaccines Revenue by Company (2018-2023)
6.1.2 North America Infectious Vaccines Sales Quantity by Company (2018-2023)
6.2 North America Infectious Vaccines Market Size by Type
6.2.1 North America Infectious Vaccines Sales Quantity by Type (2018-2034)
6.2.2 North America Infectious Vaccines Revenue by Type (2018-2034)
6.3 North America Infectious Vaccines Market Size by Application
6.3.1 North America Infectious Vaccines Sales Quantity by Application (2018-2034)
6.3.2 North America Infectious Vaccines Revenue by Application (2018-2034)
6.4 North America Infectious Vaccines Market Size by Country
6.4.1 North America Infectious Vaccines Revenue by Country: 2018 VS 2024 VS 2034
6.4.2 North America Infectious Vaccines Revenue by Country (2018-2034)
6.4.3 North America Infectious Vaccines Sales Quantity by Country (2018-2034)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Infectious Vaccines Sales by Company
7.1.1 Europe Infectious Vaccines Sales Quantity by Company (2018-2023)
7.1.2 Europe Infectious Vaccines Revenue by Company (2018-2023)
7.2 Europe Infectious Vaccines Market Size by Type
7.2.1 Europe Infectious Vaccines Sales Quantity by Type (2018-2034)
7.2.2 Europe Infectious Vaccines Revenue by Type (2018-2034)
7.3 Europe Infectious Vaccines Market Size by Application
7.3.1 Europe Infectious Vaccines Sales Quantity by Application (2018-2034)
7.3.2 Europe Infectious Vaccines Revenue by Application (2018-2034)
7.4 Europe Infectious Vaccines Market Size by Country
7.4.1 Europe Infectious Vaccines Revenue by Country: 2018 VS 2024 VS 2034
7.4.2 Europe Infectious Vaccines Revenue by Country (2018-2034)
7.4.3 Europe Infectious Vaccines Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Infectious Vaccines Sales by Company
8.1.1 China Infectious Vaccines Sales Quantity by Company (2018-2023)
8.1.2 China Infectious Vaccines Revenue by Company (2018-2023)
8.2 China Infectious Vaccines Market Size by Type
8.2.1 China Infectious Vaccines Sales Quantity by Type (2018-2034)
8.2.2 China Infectious Vaccines Revenue by Type (2018-2034)
8.3 China Infectious Vaccines Market Size by Application
8.3.1 China Infectious Vaccines Sales Quantity by Application (2018-2034)
8.3.2 China Infectious Vaccines Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Infectious Vaccines Sales by Company
9.1.1 APAC Infectious Vaccines Sales Quantity by Company (2018-2023)
9.1.2 APAC Infectious Vaccines Revenue by Company (2018-2023)
9.2 APAC Infectious Vaccines Market Size by Type
9.2.1 APAC Infectious Vaccines Sales Quantity by Type (2018-2034)
9.2.2 APAC Infectious Vaccines Revenue by Type (2018-2034)
9.3 APAC Infectious Vaccines Market Size by Application
9.3.1 APAC Infectious Vaccines Sales Quantity by Application (2018-2034)
9.3.2 APAC Infectious Vaccines Revenue by Application (2018-2034)
9.4 APAC Infectious Vaccines Market Size by Region
9.4.1 APAC Infectious Vaccines Revenue by Region: 2018 VS 2024 VS 2034
9.4.2 APAC Infectious Vaccines Revenue by Region (2018-2034)
9.4.3 APAC Infectious Vaccines Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Infectious Vaccines Sales by Company
10.1.1 Middle East, Africa and Latin America Infectious Vaccines Sales Quantity by Company (2018-2023)
10.1.2 Middle East, Africa and Latin America Infectious Vaccines Revenue by Company (2018-2023)
10.2 Middle East, Africa and Latin America Infectious Vaccines Market Size by Type
10.2.1 Middle East, Africa and Latin America Infectious Vaccines Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Infectious Vaccines Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Infectious Vaccines Market Size by Application
10.3.1 Middle East, Africa and Latin America Infectious Vaccines Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Infectious Vaccines Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Infectious Vaccines Market Size by Country
10.4.1 Middle East, Africa and Latin America Infectious Vaccines Revenue by Country: 2018 VS 2024 VS 2034
10.4.2 Middle East, Africa and Latin America Infectious Vaccines Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Infectious Vaccines Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 CSL Limited (Australia)
11.1.1 CSL Limited (Australia) Company Information
11.1.2 CSL Limited (Australia) Overview
11.1.3 CSL Limited (Australia) Infectious Vaccines Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.1.4 CSL Limited (Australia) Infectious Vaccines Products and Services
11.1.5 CSL Limited (Australia) Infectious Vaccines SWOT Analysis
11.1.6 CSL Limited (Australia) Recent Developments
11.2 Bavarian Nordic (Denmark)
11.2.1 Bavarian Nordic (Denmark) Company Information
11.2.2 Bavarian Nordic (Denmark) Overview
11.2.3 Bavarian Nordic (Denmark) Infectious Vaccines Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.2.4 Bavarian Nordic (Denmark) Infectious Vaccines Products and Services
11.2.5 Bavarian Nordic (Denmark) Infectious Vaccines SWOT Analysis
11.2.6 Bavarian Nordic (Denmark) Recent Developments
11.3 GlaxoSmithKline plc. (U.K.)
11.3.1 GlaxoSmithKline plc. (U.K.) Company Information
11.3.2 GlaxoSmithKline plc. (U.K.) Overview
11.3.3 GlaxoSmithKline plc. (U.K.) Infectious Vaccines Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.3.4 GlaxoSmithKline plc. (U.K.) Infectious Vaccines Products and Services
11.3.5 GlaxoSmithKline plc. (U.K.) Infectious Vaccines SWOT Analysis
11.3.6 GlaxoSmithKline plc. (U.K.) Recent Developments
11.4 Emergent Bio Solutions Inc. (U.S.)
11.4.1 Emergent Bio Solutions Inc. (U.S.) Company Information
11.4.2 Emergent Bio Solutions Inc. (U.S.) Overview
11.4.3 Emergent Bio Solutions Inc. (U.S.) Infectious Vaccines Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.4.4 Emergent Bio Solutions Inc. (U.S.) Infectious Vaccines Products and Services
11.4.5 Emergent Bio Solutions Inc. (U.S.) Infectious Vaccines SWOT Analysis
11.4.6 Emergent Bio Solutions Inc. (U.S.) Recent Developments
11.5 MedImmune LLC (U.S.)
11.5.1 MedImmune LLC (U.S.) Company Information
11.5.2 MedImmune LLC (U.S.) Overview
11.5.3 MedImmune LLC (U.S.) Infectious Vaccines Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.5.4 MedImmune LLC (U.S.) Infectious Vaccines Products and Services
11.5.5 MedImmune LLC (U.S.) Infectious Vaccines SWOT Analysis
11.5.6 MedImmune LLC (U.S.) Recent Developments
11.6 Johnson and Johnson (U.S.)
11.6.1 Johnson and Johnson (U.S.) Company Information
11.6.2 Johnson and Johnson (U.S.) Overview
11.6.3 Johnson and Johnson (U.S.) Infectious Vaccines Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.6.4 Johnson and Johnson (U.S.) Infectious Vaccines Products and Services
11.6.5 Johnson and Johnson (U.S.) Infectious Vaccines SWOT Analysis
11.6.6 Johnson and Johnson (U.S.) Recent Developments
11.7 Novartis AG (Switzerland)
11.7.1 Novartis AG (Switzerland) Company Information
11.7.2 Novartis AG (Switzerland) Overview
11.7.3 Novartis AG (Switzerland) Infectious Vaccines Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.7.4 Novartis AG (Switzerland) Infectious Vaccines Products and Services
11.7.5 Novartis AG (Switzerland) Infectious Vaccines SWOT Analysis
11.7.6 Novartis AG (Switzerland) Recent Developments
11.8 Merck and Company (U.S.)
11.8.1 Merck and Company (U.S.) Company Information
11.8.2 Merck and Company (U.S.) Overview
11.8.3 Merck and Company (U.S.) Infectious Vaccines Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.8.4 Merck and Company (U.S.) Infectious Vaccines Products and Services
11.8.5 Merck and Company (U.S.) Infectious Vaccines SWOT Analysis
11.8.6 Merck and Company (U.S.) Recent Developments
11.9 Sanofi Pasteur (France)
11.9.1 Sanofi Pasteur (France) Company Information
11.9.2 Sanofi Pasteur (France) Overview
11.9.3 Sanofi Pasteur (France) Infectious Vaccines Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.9.4 Sanofi Pasteur (France) Infectious Vaccines Products and Services
11.9.5 Sanofi Pasteur (France) Infectious Vaccines SWOT Analysis
11.9.6 Sanofi Pasteur (France) Recent Developments
11.10 Pfizer Inc. (U.S.)
11.10.1 Pfizer Inc. (U.S.) Company Information
11.10.2 Pfizer Inc. (U.S.) Overview
11.10.3 Pfizer Inc. (U.S.) Infectious Vaccines Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.10.4 Pfizer Inc. (U.S.) Infectious Vaccines Products and Services
11.10.5 Pfizer Inc. (U.S.) Infectious Vaccines SWOT Analysis
11.10.6 Pfizer Inc. (U.S.) Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Infectious Vaccines Value Chain Analysis
12.2 Infectious Vaccines Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Infectious Vaccines Production Mode & Process
12.4 Infectious Vaccines Sales and Marketing
12.4.1 Infectious Vaccines Sales Channels
12.4.2 Infectious Vaccines Distributors
12.5 Infectious Vaccines Customers
13 Market Dynamics
13.1 Infectious Vaccines Industry Trends
13.2 Infectious Vaccines Market Drivers
13.3 Infectious Vaccines Market Challenges
13.4 Infectious Vaccines Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Infectious Vaccines Market Size Growth Rate (CAGR) by Type, 2018 VS 2024 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Preventive Vaccine
Table 3. Major Manufacturers of Therapeutic Vaccine
Table 4. Global Infectious Vaccines Market Size Growth Rate (CAGR) by Application, 2018 VS 2024 VS 2034 (US$ Million)
Table 5. Global Infectious Vaccines Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 6. Global Infectious Vaccines Revenue by Region (2018-2023) & (US$ Million)
Table 7. Global Infectious Vaccines Revenue Market Share by Region (2018-2023)
Table 8. Global Infectious Vaccines Revenue by Region (2024-2034) & (US$ Million)
Table 9. Global Infectious Vaccines Revenue Market Share by Region (2024-2034)
Table 10. Global Infectious Vaccines Sales Quantity by Region: 2018 VS 2024 VS 2034 (K Units)
Table 11. Global Infectious Vaccines Sales by Region (2018-2023) & (K Units)
Table 12. Global Infectious Vaccines Sales Market Share by Region (2018-2023)
Table 13. Global Infectious Vaccines Sales by Region (2024-2034) & (K Units)
Table 14. Global Infectious Vaccines Sales Market Share by Region (2024-2034)
Table 15. Global Infectious Vaccines Sales Quantity by Manufacturers (2018-2023) & (K Units)
Table 16. Global Infectious Vaccines Sales Quantity Share by Manufacturers (2018-2023)
Table 17. Global Infectious Vaccines Revenue by Manufacturers (2018-2023) & (US$ Million)
Table 18. Global Infectious Vaccines Revenue Share by Manufacturers (2018-2023)
Table 19. Global Infectious Vaccines Price by Manufacturers 2018-2023 (USD/Unit)
Table 20. Global Key Players of Infectious Vaccines, Industry Ranking, 2021 VS 2024
Table 21. Global Infectious Vaccines Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 22. Global Infectious Vaccines by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Infectious Vaccines as of 2024)
Table 23. Global Key Manufacturers of Infectious Vaccines, Manufacturing Base Distribution and Headquarters
Table 24. Global Key Manufacturers of Infectious Vaccines, Product Offered and Application
Table 25. Global Key Manufacturers of Infectious Vaccines, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Infectious Vaccines Sales Quantity by Type (2018-2023) & (K Units)
Table 28. Global Infectious Vaccines Sales Quantity by Type (2024-2034) & (K Units)
Table 29. Global Infectious Vaccines Sales Quantity Share by Type (2018-2023)
Table 30. Global Infectious Vaccines Sales Quantity Share by Type (2024-2034)
Table 31. Global Infectious Vaccines Revenue by Type (2018-2023) & (US$ Million)
Table 32. Global Infectious Vaccines Revenue by Type (2024-2034) & (US$ Million)
Table 33. Global Infectious Vaccines Revenue Share by Type (2018-2023)
Table 34. Global Infectious Vaccines Revenue Share by Type (2024-2034)
Table 35. Infectious Vaccines Price by Type (2018-2023) & (USD/Unit)
Table 36. Global Infectious Vaccines Price Forecast by Type (2024-2034) & (USD/Unit)
Table 37. Global Infectious Vaccines Sales Quantity by Application (2018-2023) & (K Units)
Table 38. Global Infectious Vaccines Sales Quantity by Application (2024-2034) & (K Units)
Table 39. Global Infectious Vaccines Sales Quantity Share by Application (2018-2023)
Table 40. Global Infectious Vaccines Sales Quantity Share by Application (2024-2034)
Table 41. Global Infectious Vaccines Revenue by Application (2018-2023) & (US$ Million)
Table 42. Global Infectious Vaccines Revenue by Application (2024-2034) & (US$ Million)
Table 43. Global Infectious Vaccines Revenue Share by Application (2018-2023)
Table 44. Global Infectious Vaccines Revenue Share by Application (2024-2034)
Table 45. Infectious Vaccines Price by Application (2018-2023) & (USD/Unit)
Table 46. Global Infectious Vaccines Price Forecast by Application (2024-2034) & (USD/Unit)
Table 47. North America Infectious Vaccines Revenue by Company (2018-2023) & (US$ Million)
Table 48. North America Infectious Vaccines Sales Quantity by Company (2018-2023) & (K Units)
Table 49. North America Infectious Vaccines Sales Quantity by Type (2018-2023) & (K Units)
Table 50. North America Infectious Vaccines Sales Quantity by Type (2024-2034) & (K Units)
Table 51. North America Infectious Vaccines Revenue by Type (2018-2023) & (US$ Million)
Table 52. North America Infectious Vaccines Revenue by Type (2024-2034) & (US$ Million)
Table 53. North America Infectious Vaccines Sales Quantity by Application (2018-2023) & (K Units)
Table 54. North America Infectious Vaccines Sales Quantity by Application (2024-2034) & (K Units)
Table 55. North America Infectious Vaccines Revenue by Application (2018-2023) & (US$ Million)
Table 56. North America Infectious Vaccines Revenue by Application (2024-2034) & (US$ Million)
Table 57. North America Infectious Vaccines Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 58. North America Infectious Vaccines Revenue by Country (2018-2023) & (US$ Million)
Table 59. North America Infectious Vaccines Revenue by Country (2024-2034) & (US$ Million)
Table 60. North America Infectious Vaccines Sales Quantity by Country (2018-2023) & (K Units)
Table 61. North America Infectious Vaccines Sales Quantity by Country (2024-2034) & (K Units)
Table 62. Europe Infectious Vaccines Sales Quantity by Company (2018-2023) & (K Units)
Table 63. Europe Infectious Vaccines Revenue by Company (2018-2023) & (US$ Million)
Table 64. Europe Infectious Vaccines Sales Quantity by Type (2018-2023) & (K Units)
Table 65. Europe Infectious Vaccines Sales Quantity by Type (2024-2034) & (K Units)
Table 66. Europe Infectious Vaccines Revenue by Type (2018-2023) & (US$ Million)
Table 67. Europe Infectious Vaccines Revenue by Type (2024-2034) & (US$ Million)
Table 68. Europe Infectious Vaccines Sales Quantity by Application (2018-2023) & (K Units)
Table 69. Europe Infectious Vaccines Sales Quantity by Application (2024-2034) & (K Units)
Table 70. Europe Infectious Vaccines Revenue by Application (2018-2023) & (US$ Million)
Table 71. Europe Infectious Vaccines Revenue by Application (2024-2034) & (US$ Million)
Table 72. Europe Infectious Vaccines Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 73. Europe Infectious Vaccines Revenue by Country (2018-2023) & (US$ Million)
Table 74. Europe Infectious Vaccines Revenue by Country (2024-2034) & (US$ Million)
Table 75. Europe Infectious Vaccines Sales Quantity by Country (2018-2023) & (K Units)
Table 76. Europe Infectious Vaccines Sales Quantity by Country (2024-2034) & (K Units)
Table 77. China Infectious Vaccines Sales Quantity by Company (2018-2023) & (K Units)
Table 78. China Infectious Vaccines Revenue by Company (2018-2023) & (US$ Million)
Table 79. China Infectious Vaccines Sales Quantity by Type (2018-2023) & (K Units)
Table 80. China Infectious Vaccines Sales Quantity by Type (2024-2034) & (K Units)
Table 81. China Infectious Vaccines Revenue by Type (2018-2023) & (US$ Million)
Table 82. China Infectious Vaccines Revenue by Type (2024-2034) & (US$ Million)
Table 83. China Infectious Vaccines Sales Quantity by Application (2018-2023) & (K Units)
Table 84. China Infectious Vaccines Sales Quantity by Application (2024-2034) & (K Units)
Table 85. China Infectious Vaccines Revenue by Application (2018-2023) & (US$ Million)
Table 86. China Infectious Vaccines Revenue by Application (2024-2034) & (US$ Million)
Table 87. APAC Infectious Vaccines Sales Quantity by Company (2018-2023) & (K Units)
Table 88. APAC Infectious Vaccines Revenue by Company (2018-2023) & (US$ Million)
Table 89. APAC Infectious Vaccines Sales Quantity by Type (2018-2023) & (K Units)
Table 90. APAC Infectious Vaccines Sales Quantity by Type (2024-2034) & (K Units)
Table 91. APAC Infectious Vaccines Revenue by Type (2018-2023) & (US$ Million)
Table 92. APAC Infectious Vaccines Revenue by Type (2024-2034) & (US$ Million)
Table 93. APAC Infectious Vaccines Sales Quantity by Application (2018-2023) & (K Units)
Table 94. APAC Infectious Vaccines Sales Quantity by Application (2024-2034) & (K Units)
Table 95. APAC Infectious Vaccines Revenue by Application (2018-2023) & (US$ Million)
Table 96. APAC Infectious Vaccines Revenue by Application (2024-2034) & (US$ Million)
Table 97. APAC Infectious Vaccines Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 98. APAC Infectious Vaccines Revenue by Region (2018-2023) & (US$ Million)
Table 99. APAC Infectious Vaccines Revenue by Region (2024-2034) & (US$ Million)
Table 100. APAC Infectious Vaccines Sales Quantity by Region (2018-2023) & (K Units)
Table 101. APAC Infectious Vaccines Sales Quantity by Region (2024-2034) & (K Units)
Table 102. Middle East, Africa and Latin America Infectious Vaccines Sales Quantity by Company (2018-2023) & (K Units)
Table 103. Middle East, Africa and Latin America Infectious Vaccines Revenue by Company (2018-2023) & (US$ Million)
Table 104. Middle East, Africa and Latin America Infectious Vaccines Sales Quantity by Type (2018-2023) & (K Units)
Table 105. Middle East, Africa and Latin America Infectious Vaccines Sales Quantity by Type (2024-2034) & (K Units)
Table 106. Middle East, Africa and Latin America Infectious Vaccines Revenue by Type (2018-2023) & (US$ Million)
Table 107. Middle East, Africa and Latin America Infectious Vaccines Revenue by Type (2024-2034) & (US$ Million)
Table 108. Middle East, Africa and Latin America Infectious Vaccines Sales Quantity by Application (2018-2023) & (K Units)
Table 109. Middle East, Africa and Latin America Infectious Vaccines Sales Quantity by Application (2024-2034) & (K Units)
Table 110. Middle East, Africa and Latin America Infectious Vaccines Revenue by Application (2018-2023) & (US$ Million)
Table 111. Middle East, Africa and Latin America Infectious Vaccines Revenue by Application (2024-2034) & (US$ Million)
Table 112. Middle East, Africa and Latin America Infectious Vaccines Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 113. Middle East, Africa and Latin America Infectious Vaccines Revenue by Country (2018-2023) & (US$ Million)
Table 114. Middle East, Africa and Latin America Infectious Vaccines Revenue by Country (2024-2034) & (US$ Million)
Table 115. Middle East, Africa and Latin America Infectious Vaccines Sales Quantity by Country (2018-2023) & (K Units)
Table 116. Middle East, Africa and Latin America Infectious Vaccines Sales Quantity by Country (2024-2034) & (K Units)
Table 117. CSL Limited (Australia) Company Information
Table 118. CSL Limited (Australia) Description and Overview
Table 119. CSL Limited (Australia) Infectious Vaccines Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 120. CSL Limited (Australia) Infectious Vaccines Product and Services
Table 121. CSL Limited (Australia) Infectious Vaccines SWOT Analysis
Table 122. CSL Limited (Australia) Recent Developments
Table 123. Bavarian Nordic (Denmark) Company Information
Table 124. Bavarian Nordic (Denmark) Description and Overview
Table 125. Bavarian Nordic (Denmark) Infectious Vaccines Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 126. Bavarian Nordic (Denmark) Infectious Vaccines Product and Services
Table 127. Bavarian Nordic (Denmark) Infectious Vaccines SWOT Analysis
Table 128. Bavarian Nordic (Denmark) Recent Developments
Table 129. GlaxoSmithKline plc. (U.K.) Company Information
Table 130. GlaxoSmithKline plc. (U.K.) Description and Overview
Table 131. GlaxoSmithKline plc. (U.K.) Infectious Vaccines Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 132. GlaxoSmithKline plc. (U.K.) Infectious Vaccines Product and Services
Table 133. GlaxoSmithKline plc. (U.K.) Infectious Vaccines SWOT Analysis
Table 134. GlaxoSmithKline plc. (U.K.) Recent Developments
Table 135. Emergent Bio Solutions Inc. (U.S.) Company Information
Table 136. Emergent Bio Solutions Inc. (U.S.) Description and Overview
Table 137. Emergent Bio Solutions Inc. (U.S.) Infectious Vaccines Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 138. Emergent Bio Solutions Inc. (U.S.) Infectious Vaccines Product and Services
Table 139. Emergent Bio Solutions Inc. (U.S.) Infectious Vaccines SWOT Analysis
Table 140. Emergent Bio Solutions Inc. (U.S.) Recent Developments
Table 141. MedImmune LLC (U.S.) Company Information
Table 142. MedImmune LLC (U.S.) Description and Overview
Table 143. MedImmune LLC (U.S.) Infectious Vaccines Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 144. MedImmune LLC (U.S.) Infectious Vaccines Product and Services
Table 145. MedImmune LLC (U.S.) Infectious Vaccines SWOT Analysis
Table 146. MedImmune LLC (U.S.) Recent Developments
Table 147. Johnson and Johnson (U.S.) Company Information
Table 148. Johnson and Johnson (U.S.) Description and Overview
Table 149. Johnson and Johnson (U.S.) Infectious Vaccines Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 150. Johnson and Johnson (U.S.) Infectious Vaccines Product and Services
Table 151. Johnson and Johnson (U.S.) Infectious Vaccines SWOT Analysis
Table 152. Johnson and Johnson (U.S.) Recent Developments
Table 153. Novartis AG (Switzerland) Company Information
Table 154. Novartis AG (Switzerland) Description and Overview
Table 155. Novartis AG (Switzerland) Infectious Vaccines Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 156. Novartis AG (Switzerland) Infectious Vaccines Product and Services
Table 157. Novartis AG (Switzerland) Infectious Vaccines SWOT Analysis
Table 158. Novartis AG (Switzerland) Recent Developments
Table 159. Merck and Company (U.S.) Company Information
Table 160. Merck and Company (U.S.) Description and Overview
Table 161. Merck and Company (U.S.) Infectious Vaccines Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 162. Merck and Company (U.S.) Infectious Vaccines Product and Services
Table 163. Merck and Company (U.S.) Infectious Vaccines SWOT Analysis
Table 164. Merck and Company (U.S.) Recent Developments
Table 165. Sanofi Pasteur (France) Company Information
Table 166. Sanofi Pasteur (France) Description and Overview
Table 167. Sanofi Pasteur (France) Infectious Vaccines Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 168. Sanofi Pasteur (France) Infectious Vaccines Product and Services
Table 169. Sanofi Pasteur (France) Infectious Vaccines SWOT Analysis
Table 170. Sanofi Pasteur (France) Recent Developments
Table 171. Pfizer Inc. (U.S.) Company Information
Table 172. Pfizer Inc. (U.S.) Description and Overview
Table 173. Pfizer Inc. (U.S.) Infectious Vaccines Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 174. Pfizer Inc. (U.S.) Infectious Vaccines Product and Services
Table 175. Pfizer Inc. (U.S.) Infectious Vaccines SWOT Analysis
Table 176. Pfizer Inc. (U.S.) Recent Developments
Table 177. Key Raw Materials Lists
Table 178. Raw Materials Key Suppliers Lists
Table 179. Infectious Vaccines Distributors List
Table 180. Infectious Vaccines Customers List
Table 181. Infectious Vaccines Market Trends
Table 182. Infectious Vaccines Market Drivers
Table 183. Infectious Vaccines Market Challenges
Table 184. Infectious Vaccines Market Restraints
Table 185. Research Programs/Design for This Report
Table 186. Key Data Information from Secondary Sources
Table 187. Key Data Information from Primary Sources
List of Figures
Figure 1. Infectious Vaccines Product Picture
Figure 2. Global Infectious Vaccines Market Size Growth Rate by Type, 2018 VS 2024 VS 2034 (US$ Million)
Figure 3. Global Infectious Vaccines Market Share by Type in 2024 & 2034
Figure 4. Preventive Vaccine Product Picture
Figure 5. Therapeutic Vaccine Product Picture
Figure 6. Global Infectious Vaccines Market Size Growth Rate by Application, 2018 VS 2024 VS 2034 (US$ Million)
Figure 7. Global Infectious Vaccines Market Share by Application in 2024 & 2034
Figure 8. Adults
Figure 9. Pediatrics
Figure 10. Infectious Vaccines Report Years Considered
Figure 11. Global Infectious Vaccines Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 12. Global Infectious Vaccines Revenue 2018-2034 (US$ Million)
Figure 13. Global Infectious Vaccines Revenue Market Share by Region in Percentage: 2024 Versus 2034
Figure 14. Global Infectious Vaccines Sales Quantity 2018-2034 (K Units)
Figure 15. Global Infectious Vaccines Sales Quantity Market Share by Region (2018-2023)
Figure 16. Global Infectious Vaccines Sales Quantity Market Share by Region (2024-2034)
Figure 17. North America Infectious Vaccines Sales Quantity YoY (2018-2034) & (K Units)
Figure 18. North America Infectious Vaccines Revenue YoY (2018-2034) & (US$ Million)
Figure 19. Europe Infectious Vaccines Sales Quantity YoY (2018-2034) & (K Units)
Figure 20. Europe Infectious Vaccines Revenue YoY (2018-2034) & (US$ Million)
Figure 21. China Infectious Vaccines Sales Quantity YoY (2018-2034) & (K Units)
Figure 22. China Infectious Vaccines Revenue YoY (2018-2034) & (US$ Million)
Figure 23. APAC Infectious Vaccines Sales Quantity YoY (2018-2034) & (K Units)
Figure 24. APAC Infectious Vaccines Revenue YoY (2018-2034) & (US$ Million)
Figure 25. Middle East, Africa and Latin America Infectious Vaccines Sales Quantity YoY (2018-2034) & (K Units)
Figure 26. Middle East, Africa and Latin America Infectious Vaccines Revenue YoY (2018-2034) & (US$ Million)
Figure 27. The Top 10 and Top 5 Players Market Share by Infectious Vaccines Sales Quantity in 2024
Figure 28. The Top 10 and Top 5 Players Market Share by Infectious Vaccines Revenue in 2024
Figure 29. Infectious Vaccines Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2024
Figure 30. Global Infectious Vaccines Sales Quantity Market Share by Type (2018-2034)
Figure 31. Global Infectious Vaccines Revenue Market Share by Type (2018-2034)
Figure 32. Global Infectious Vaccines Sales Quantity Market Share by Application (2018-2034)
Figure 33. Global Infectious Vaccines Revenue Market Share by Application (2018-2034)
Figure 34. North America Infectious Vaccines Revenue Market Share by Company in 2024
Figure 35. North America Infectious Vaccines Sales Quantity Market Share by Company in 2024
Figure 36. North America Infectious Vaccines Sales Quantity Market Share by Type (2018-2034)
Figure 37. North America Infectious Vaccines Revenue Market Share by Type (2018-2034)
Figure 38. North America Infectious Vaccines Sales Quantity Market Share by Application (2018-2034)
Figure 39. North America Infectious Vaccines Revenue Market Share by Application (2018-2034)
Figure 40. North America Infectious Vaccines Revenue Share by Country (2018-2034)
Figure 41. North America Infectious Vaccines Sales Quantity Share by Country (2018-2034)
Figure 42. U.S. Infectious Vaccines Revenue (2018-2034) & (US$ Million)
Figure 43. Canada Infectious Vaccines Revenue (2018-2034) & (US$ Million)
Figure 44. Europe Infectious Vaccines Sales Quantity Market Share by Company in 2024
Figure 45. Europe Infectious Vaccines Revenue Market Share by Company in 2024
Figure 46. Europe Infectious Vaccines Sales Quantity Market Share by Type (2018-2034)
Figure 47. Europe Infectious Vaccines Revenue Market Share by Type (2018-2034)
Figure 48. Europe Infectious Vaccines Sales Quantity Market Share by Application (2018-2034)
Figure 49. Europe Infectious Vaccines Revenue Market Share by Application (2018-2034)
Figure 50. Europe Infectious Vaccines Revenue Share by Country (2018-2034)
Figure 51. Europe Infectious Vaccines Sales Quantity Share by Country (2018-2034)
Figure 52. Germany Infectious Vaccines Revenue (2018-2034) & (US$ Million)
Figure 53. France Infectious Vaccines Revenue (2018-2034) & (US$ Million)
Figure 54. U.K. Infectious Vaccines Revenue (2018-2034) & (US$ Million)
Figure 55. Italy Infectious Vaccines Revenue (2018-2034) & (US$ Million)
Figure 56. Russia Infectious Vaccines Revenue (2018-2034) & (US$ Million)
Figure 57. China Infectious Vaccines Sales Quantity Market Share by Company in 2024
Figure 58. China Infectious Vaccines Revenue Market Share by Company in 2024
Figure 59. China Infectious Vaccines Sales Quantity Market Share by Type (2018-2034)
Figure 60. China Infectious Vaccines Revenue Market Share by Type (2018-2034)
Figure 61. China Infectious Vaccines Sales Quantity Market Share by Application (2018-2034)
Figure 62. China Infectious Vaccines Revenue Market Share by Application (2018-2034)
Figure 63. APAC Infectious Vaccines Sales Quantity Market Share by Company in 2024
Figure 64. APAC Infectious Vaccines Revenue Market Share by Company in 2024
Figure 65. APAC Infectious Vaccines Sales Quantity Market Share by Type (2018-2034)
Figure 66. APAC Infectious Vaccines Revenue Market Share by Type (2018-2034)
Figure 67. APAC Infectious Vaccines Sales Quantity Market Share by Application (2018-2034)
Figure 68. APAC Infectious Vaccines Revenue Market Share by Application (2018-2034)
Figure 69. APAC Infectious Vaccines Revenue Share by Region (2018-2034)
Figure 70. APAC Infectious Vaccines Sales Quantity Share by Region (2018-2034)
Figure 71. Japan Infectious Vaccines Revenue (2018-2034) & (US$ Million)
Figure 72. South Korea Infectious Vaccines Revenue (2018-2034) & (US$ Million)
Figure 73. China Taiwan Infectious Vaccines Revenue (2018-2034) & (US$ Million)
Figure 74. Southeast Asia Infectious Vaccines Revenue (2018-2034) & (US$ Million)
Figure 75. India Infectious Vaccines Revenue (2018-2034) & (US$ Million)
Figure 76. Middle East, Africa and Latin America Infectious Vaccines Sales Quantity Market Share by Company in 2024
Figure 77. Middle East, Africa and Latin America Infectious Vaccines Revenue Market Share by Company in 2024
Figure 78. Middle East, Africa and Latin America Infectious Vaccines Sales Quantity Market Share by Type (2018-2034)
Figure 79. Middle East, Africa and Latin America Infectious Vaccines Revenue Market Share by Type (2018-2034)
Figure 80. Middle East, Africa and Latin America Infectious Vaccines Sales Quantity Market Share by Application (2018-2034)
Figure 81. Middle East, Africa and Latin America Infectious Vaccines Revenue Market Share by Application (2018-2034)
Figure 82. Middle East, Africa and Latin America Infectious Vaccines Sales Quantity Share by Country (2018-2034)
Figure 83. Middle East, Africa and Latin America Infectious Vaccines Revenue Share by Country (2018-2034)
Figure 84. Brazil Infectious Vaccines Revenue (2018-2034) & (US$ Million)
Figure 85. Mexico Infectious Vaccines Revenue (2018-2034) & (US$ Million)
Figure 86. Turkey Infectious Vaccines Revenue (2018-2034) & (US$ Million)
Figure 87. Israel Infectious Vaccines Revenue (2018-2034) & (US$ Million)
Figure 88. GCC Countries Infectious Vaccines Revenue (2018-2034) & (US$ Million)
Figure 89. Infectious Vaccines Value Chain
Figure 90. Infectious Vaccines Production Process
Figure 91. Channels of Distribution (Direct Vs Distribution)
Figure 92. Distributors Profiles
Figure 93. Bottom-up and Top-down Approaches for This Report
Figure 94. Data Triangulation
Figure 95. Key Executives Interviewed